Search results for "Peptide receptor"

showing 10 items of 24 documents

1st World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23-26, 2011, Zentralklinik Bad Berka, Germany

2011

EditorialPeptide receptorbusiness.industryRadionuclide therapyMedicinePhysiologybusinessBioinformaticsWorld Journal of Nuclear Medicine
researchProduct

90Y radioembolization in the treatment of neuroendocrine neoplasms: Results of an international multicenter retrospective study.

2021

In neuroendocrine neoplasms (NEN), the presence of distant metastases has a severe impact on survival leading to a relevant decrease of the 5-year survival rate. Here, 90Y radioembolization (RE) might be an important treatment option, however, data to support clinical benefits for RE are scarce. Therefore, the purpose of this study was to analyze the use of RE in NEN patients with hepatic metastases in an international, multi-center retrospective analysis and assess the potential role of RE in a multimodal treatment concept. Methods: 297 angiographic evaluations in NEN patients prior to RE were analyzed. Baseline characteristics and parameters derived from imaging evaluation and RE were ana…

Entire populationmedicine.medical_specialtyPeptide receptorbusiness.industryRetrospective cohort studyHepatologyGastroenterologyLog-rank testStatistical significanceInternal medicineRadionuclide therapymedicineRadiology Nuclear Medicine and imagingbusinessSurvival rateJournal of Nuclear Medicine
researchProduct

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

2019

Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyPeptide receptormedicine.medical_treatmentNeuroendocrine tumorsOctreotide030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyInternal medicineOrganometallic CompoundsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingAdverse effectCapecitabineAgedChemotherapybusiness.industryIncidence (epidemiology)Therapeutic effectChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumors030220 oncology & carcinogenesisConcomitantRadionuclide therapyFemaleRadiopharmaceuticalsbusinessClinical Nuclear Medicine
researchProduct

Natriuretic peptide system expression in murine and human submandibular salivary glands: a study of the spatial localisation of ANB, BNP, CNP and the…

2019

AbstractThe natriuretic peptide (NP) system comprises of three ligands, the Atrial Natriuretic Peptide (ANP), Brain Natriuretic peptide (BNP) and C-type Natriuretic peptide (CNP), and three natriuretic peptide receptors, NPRA, NPRB and NPRC. Here we present a comprehensive study of the natriuretic peptide system in healthy murine and human submandibular salivary glands (SMGs). We show CNP is the dominant NP in mouse and human SMG and is expressed together with NP receptors in ducts, autonomic nerves and the microvasculature of the gland, suggesting CNP autocrine signalling may take place in some of these glandular structures. These data suggest the NP system may control salivary gland funct…

MaleSettore BIO/17 - Istologia0301 basic medicinemedicine.medical_specialtyHistologyReceptors PeptidePhysiologymedicine.drug_classAtrial natriuretic peptide ANPNatriuretic peptide receptor B NPRBMice03 medical and health sciences0302 clinical medicineAtrial natriuretic peptideInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideAnimalsHumansAutonomic nervous systemB-type natriuretic peptide BNPNatriuretic peptide receptor C NPRCAutocrine signallingReceptorSalivary glandSubmandibular glandSalivary glandC-type natriuretic peptide CNPChemistryNatriuretic Peptide C-TypeCell BiologyGeneral MedicineNatriuretic peptide receptor A NPRABrain natriuretic peptideSubmandibular glandNeoplasm Proteins030104 developmental biologymedicine.anatomical_structureEndocrinologyOral squamous cell carcinoma030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleMouth NeoplasmsAtrial Natriuretic FactorHomeostasisJournal of Molecular Histology
researchProduct

Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Trea…

2022

The obesity pandemic is accompanied by increased risk of developing metabolic syndrome (MetS) and related conditions: non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), type 2 diabetes mellitus (T2DM) and cardiovascular (CV) disease (CVD). Lifestyle, as well as an imbalance of energy intake/expenditure, genetic predisposition, and epigenetics could lead to a dysmetabolic milieu, which is the cornerstone for the development of cardiometabolic complications. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAs promote positive effects on most components of the “ cardiometabolic continuum” an…

Metabolic SyndromePharmacologyglucagon-like peptide-1 receptor agonists glucose-dependent insulinotropic polypeptide receptor agonists non-alcoholic fatty liver disease obesity prediabetes tirzepatide type 2 diabetes mellitusGlucagon-Like Peptide-1 ReceptorPrediabetic StateGlucoseDiabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide 1HumansPharmacology (medical)ObesityPeptidesCardiology and Cardiovascular MedicineJournal of Cardiovascular Pharmacology and Therapeutics
researchProduct

Participation of Two Ser-Ser-Phe-Tyr Repeats in Interleukin-6 (IL-6)-Binding Sites of the Human IL-6 Receptor

1996

The alpha-subunit of interleukin-6 (IL-6) receptor is a member of the hematopoietin receptor family. The alignment of its amino acid sequence with those of other members of this family (human somatotropin receptor/murine IL-3 receptor beta and human IL-2 receptor beta) has suggested that amino acids included in two SSFY repeats found in each of its hematopoietin receptor domains, contribute to the binding of the ligand. The involvement of these amino acids in IL-6 binding and signal transduction was studied by site-directed mutagenesis and molecular modelling. We present a computer-derived three-dimensional model of the IL-6/IL-6 receptor complex based on the structure of the human somatotr…

Models MolecularReceptor complexMolecular Sequence DataB-cell receptorInterleukin 5 receptor alpha subunitBiologyBiochemistryMiceAntigens CDTumor Cells CulturedEnzyme-linked receptorAnimalsHumans5-HT5A receptorAmino Acid SequenceNuclear receptor co-repressor 1Binding SitesBase SequenceInterleukin-6Antibodies MonoclonalReceptors InterleukinInterleukin-13 receptorReceptors Interleukin-6Molecular biologyBiochemistryMutationRabbitsEpitope MappingRelaxin/insulin-like family peptide receptor 2Signal TransductionEuropean Journal of Biochemistry
researchProduct

Prevention and Management of Hormonal Crisis during Theragnosis with LU-DOTA-TATE in Neuroendocrine Tumors. A Systematic Review and Approach Proposal.

2020

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTR) on their cell surface. The first-line pharmacological treatment for inoperable metastatic functioning well-differentiated NETs are somatostatin analogs. On second line, Lu-DOTA-TATE (177Lu-DOTA0 Tyr 3 octreotate) has shown stabilization of the disease and an increase in progression free survival, as well as effectiveness in controlling symptoms and increasing quality of life. The management of functional NETs before and during LU-DOTA-TATE treatment is specially challenging, as several complications such as severe carcinoid and catecholamine crisis have been described. The aim of this review is to establish pr…

Oncologymedicine.medical_specialtycatecholaminergic crisisMEDLINElcsh:Medicinecarcinoid syndrome030209 endocrinology & metabolismReviewNeuroendocrine tumors03 medical and health scienceschemistry.chemical_compound0302 clinical medicinesystematic reviewInternal medicinemedicinecarcinoid crisisProgression-free survivalDOTA-TATEpeptide receptor radionuclide therapyhormonal crisisOctreotatebusiness.industrySomatostatin receptorlcsh:RGeneral Medicinemedicine.diseaseSystematic reviewchemistry030220 oncology & carcinogenesisneuroendocrine tumorsbusiness177Lu-DOTA-TATECarcinoid syndromeJournal of clinical medicine
researchProduct

The Concise Guide To Pharmacology 2021/22: G Protein-Coupled Receptors

2021

The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will s…

RMCytoplasmic and NuclearComputer scienceDatabases PharmaceuticalHumans; Ion Channels; Ligands; Receptors Cytoplasmic and Nuclear; Receptors G-Protein-Coupled; Databases Pharmaceutical; PharmacologyReceptors Cytoplasmic and NuclearIN-VITRO CHARACTERIZATIONPharmacologyLigandsIon ChannelsNORSlaw.inventionReceptors G-Protein-CoupledG-Protein-CoupledDatabases03 medical and health sciencesCALCIUM-SENSING RECEPTOR0302 clinical medicineDELTA-OPIOID RECEPTORlawSummary informationReceptorsHumansHISTAMINE H-3 RECEPTORFATTY-ACID RECEPTORMETABOTROPIC GLUTAMATE-RECEPTOR030304 developmental biologyG protein-coupled receptorPharmacologyGONADOTROPIN-RELEASING-HORMONE0303 health sciencesClinical pharmacologyFORMYL PEPTIDE RECEPTORMUSCARINIC ACETYLCHOLINE-RECEPTOR3. Good health317 Pharmacy030220 oncology & carcinogenesisPharmaceuticalNEGATIVE ALLOSTERIC MODULATORCatalytic receptors
researchProduct

ANP differentiates between primary Submandibular Gland Squamous Cell Carcinoma and Oral Squamous Cell Carcinoma: Preliminary data

2021

The natriuretic peptide system consists of three ligands, Atrial Natriuretic Peptide (ANP), Brain Natriuretic peptide (BNP) and C-type Natriuretic peptide (CNP), and three natriuretic peptide receptors (NPR’s), NPRA, NPRB and NPRC. We investigated the expression levels of NPPA (encoding ANP) and NPR1 (encoding NPRA, the main receptor for ANP) in primary benign (pleomorphic adenoma) and malignant (squamous cell carcinoma, SCC) submandibular salivary gland (SMG) tumors, as well as in primary oral squamous cell carcinoma (OSCC). We found that the NPPA and NPR1 expression levels were significantly different in SMG SCC versus OSCC, exhibiting a significant increase in NPPA and absence of NPR1 ex…

Settore BIO/17 - IstologiaOral squamous cell carcinomaAtrial natriuretic peptide ANPNPPANatriuretic peptide receptor A NPRASubmandibular gland squamous cell carcinomaSubmandibular gland pleomorphic adenoma.
researchProduct

Identification and optimization of small molecule antagonists of vasoactive intestinal peptide receptor-1 (VIPR1).

2012

Identification, synthesis and structure-activity relationship of small-molecule VIPR1 antagonists encompassing two chemical series are described.

Vasoactive intestinal peptide (VIP)Settore MED/09 - Medicina InternaReceptors Vasoactive Intestinal Polypeptide Type IClinical BiochemistryVasoactive intestinal peptidePharmaceutical ScienceAntineoplastic AgentsThiophenesBiochemistrySmall Molecule LibrariesStructure-Activity RelationshipCell Line TumorDrug DiscoveryStructure–activity relationshipHumansReceptorMolecular BiologyChemistryVasoactive intestinal peptide receptorOrganic ChemistryBiphenyl CompoundsSmall Molecule LibrariesSmall moleculeHigh-Throughput Screening AssaysBiochemistryCell cultureVasoactive intestinal peptide receptor (VIPR)Molecular MedicineDrug Screening Assays AntitumorVIPR1Bioorganicmedicinal chemistry letters
researchProduct